Table 2 Pharmacodynamics of AS in malaria-infected women
| Â | Pregnant cases | Â | Â | ||
|---|---|---|---|---|---|
Time point | Window 1 (22-26 wks GA) | Window 2 (32-36 wks GA) | All | Non-pregnant controls | P-value* |
N | 13 | 13 | 26 | 25 | Â |
Screening | Â | Â | Â | Â | Â |
Parasitaemic - n (%) | 13 (100.0) | 13 (100.0) | 26 (100.0) | 25 (100.0) | -- |
Density (where > 0)†| 635 (264 - 842) | 516. (404 - 659) | 528 (372 - 842) | 807 (325 - 2215) | 0.21 |
0 hours (AS dosing) | Â | Â | Â | Â | Â |
Parasitaemic - n (%) | 13 (100.0) | 11 (84.6) | 24 (92.3) | 14 (56.0) | 0.0029 |
Density (where > 0)†| 414 (179 - 857) | 183 (130 - 788) | 247 (151, 828) | 371 (124 - 957) | 0.66 |
12 hours | Â | Â | Â | Â | Â |
Parasitaemic - n (%) | 3 (23.1) | 0 (0) | 3 (11.5) | 1 (4.0) | 0.61 |
Density (where > 0)†| 87 (44 - 286) | -- -- | 87 (44 - 286) | 24 -- | 0.44 |